Karnataka seeks wider price caps beyond cancer medicines on other high-cost life-saving drugs
Health Minister U.T. Khader said price rationalisation should translate into direct savings for patients, and urged the Union government to extend similar measures to other essential medicines where high treatment costs place a burden on patients.
Karnataka has called for broader price caps on high-cost life-saving drugs beyond anti-cancer medicines, following the National Pharmaceutical Pricing Authority’s (NPPA) approval to cap trade margins on certain non-scheduled anti-cancer medicines at 30% of their MRP. Health Minister U.T. Khader emphasized that price rationalisation should result in direct savings for patients and urged the Union government to extend similar measures to other essential medicines, particularly those used to treat cardiac and kidney diseases.
The NPPA’s meeting on October 8 granted in-principle approval to rationalise trade margins on non-scheduled anti-cancer medicines identified under Paragraph 19 of the Drugs (Prices Control) Order, 2013, with the Ministry of Health and Family Welfare tasked to form an expert committee to recommend medicines for price control.
Brief written by urgent.news from The Hindu - Sci-Tech's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
